Works matching IS 2160763X AND DT 2019 AND VI 8 AND IP 7

Results: 14

Population Pharmacokinetics of Rolapitant in Patients With Chemotherapy‐Induced Nausea and Vomiting.

Published in:

Clinical Pharmacology in Drug Development, 2019, v. 8, n. 7, p. 850, doi. 10.1002/cpdd.733

By:

Wang, Xiaodong;
Wang, Jing;
Zhang, Zhi‐Yi;
Kansra, Vikram

Publication type:

Article

Bioequivalence of Ertugliflozin/Sitagliptin Fixed‐Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components.

Published in:

Clinical Pharmacology in Drug Development, 2019, v. 8, n. 7, p. 884, doi. 10.1002/cpdd.722

By:

Fediuk, Daryl J.;
Matschke, Kyle;
Liang, Yali;
Pelletier, Kathleen B.;
Wei, Hua;
Shi, Haihong;
Bass, Almasa;
Hickman, Anne;
Terra, Steven G.;
Zhou, Susan;
Krishna, Rajesh;
Sahasrabudhe, Vaishali

Publication type:

Article

Correction.

Published in:: Clinical Pharmacology in Drug Development, 2019, v. 8, n. 7, p. 971, doi. 10.1002/cpdd.719
Publication type:: Article

A Randomized, Placebo‐Controlled Trial to Assess the Effects of 8 Weeks of Administration of GSK256073, a Selective GPR109A Agonist, on High‐Density Lipoprotein Cholesterol in Subjects With Dyslipidemia.

Published in:

Clinical Pharmacology in Drug Development, 2019, v. 8, n. 7, p. 871, doi. 10.1002/cpdd.704

By:

Olson, Eric J.;
Mahar, Kelly M.;
Haws, Thomas F.;
Fossler, Michael J.;
Gao, Feng;
Gouville, Anne‐Charlotte;
Sprecher, Dennis L.;
Lepore, John J.

Publication type:

Article

Pharmacokinetic Interactions Between the Fixed‐Dose Combinations of Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine and Elbasvir/Grazoprevir in Healthy Adult Participants.

Published in:

Clinical Pharmacology in Drug Development, 2019, v. 8, n. 7, p. 952, doi. 10.1002/cpdd.702

By:

Feng, Hwa‐Ping;
Guo, Zifang;
Fandozzi, Christine;
Panebianco, Deborah;
Caro, Luzelena;
Wolford, Dennis;
Dreyer, Daniel P.;
Valesky, Robert;
Martinho, Monika;
Rizk, Matthew L.;
Iwamoto, Marian;
Yeh, Wendy W.

Publication type:

Article

Assessment of Drug Interaction Potential Between the Hepatitis C Virus Direct‐Acting Antiviral Agents Elbasvir/Grazoprevir and the Nucleotide Analog Reverse‐Transcriptase Inhibitor Tenofovir Disoproxil Fumarate.

Published in:

Clinical Pharmacology in Drug Development, 2019, v. 8, n. 7, p. 962, doi. 10.1002/cpdd.701

By:

Feng, Hwa‐Ping;
Guo, Zifang;
Caro, Luzelena;
Talaty, Jennifer E.;
Mangin, Eric;
Panebianco, Deborah;
Fandozzi, Christine;
Zhu, Yali;
Marshall, William;
Huang, Xiaobi;
Hanley, William D.;
Jumes, Patricia;
Valesky, Robert;
Martinho, Monika;
Butterton, Joan R.;
Iwamoto, Marian;
Yeh, Wendy W.

Publication type:

Article

Thorough QTc Evaluation and the Safety of Supratherapeutic Doses of Odanacatib in Healthy Subjects.

Published in:

Clinical Pharmacology in Drug Development, 2019, v. 8, n. 7, p. 861, doi. 10.1002/cpdd.698

By:

McCrea, Jacqueline;
Mostoller, Kate;
Mahon, Chantal;
Liu, Chengcheng;
Liu, Fang;
Zajic, Stefan;
Panebianco, Deborah;
Chakravarthy, Manu;
Brandquist, Christine;
Gutierrez, Maria;
Stoch, S. Aubrey

Publication type:

Article

Absolute Oral Bioavailability of Glasdegib (PF‐04449913), a Smoothened Inhibitor, in Randomized Healthy Volunteers.

Published in:

Clinical Pharmacology in Drug Development, 2019, v. 8, n. 7, p. 895, doi. 10.1002/cpdd.692

By:

Shaik, Naveed;
Hee, Brian;
Liang, Yali;
LaBadie, Robert Roland

Publication type:

Article

Study on Drug‐Drug Interactions Between Chiglitazar, a Novel PPAR Pan‐Agonist, and Metformin Hydrochloride in Healthy Subjects.

Published in:

Clinical Pharmacology in Drug Development, 2019, v. 8, n. 7, p. 934, doi. 10.1002/cpdd.668

By:

Yi, Ling;
Zhang, Hua;
Zhang, Jin‐wen;
You, Xiao‐ming;
Ning, Zhi‐qiang;
Yu, Jia;
Qian, Li‐fang;
Miao, Li‐yan

Publication type:

Article

Use of Population Pharmacokinetic Analyses Among FDA‐Approved Biologics.

Published in:

Clinical Pharmacology in Drug Development, 2019, v. 8, n. 7, p. 914, doi. 10.1002/cpdd.658

By:

Ogasawara, Ken;
Alexander, G. Caleb

Publication type:

Article

Issue Information.

Published in:: Clinical Pharmacology in Drug Development, 2019, v. 8, n. 7, p. 845, doi. 10.1002/cpdd.595
Publication type:: Article

Exposure‐Response Analysis for Efficacy of Daclatasvir, Asunaprevir, and Beclabuvir Combinations in HCV‐Infected Patients.

Published in:

Clinical Pharmacology in Drug Development, 2019, v. 8, n. 7, p. 903, doi. 10.1002/cpdd.646

By:

Ueno, T.;
Osawa, M.;
Shiozaki, T.;
Green, M.;
Garimella, T.

Publication type:

Article

A Phase 1b Trial to Assess the Pharmacokinetics of Ezutromid in Pediatric Duchenne Muscular Dystrophy Patients on a Balanced Diet.

Published in:

Clinical Pharmacology in Drug Development, 2019, v. 8, n. 7, p. 922, doi. 10.1002/cpdd.642

By:

Muntoni, Francesco;
Tejura, Bina;
Spinty, Stefan;
Roper, Helen;
Hughes, Imelda;
Layton, Gary;
Davies, Kay E.;
Harriman, Shawn;
Tinsley, Jonathon

Publication type:

Article

Safety and Tolerability of the Chymase Inhibitor Fulacimstat in Patients With Left Ventricular Dysfunction After Myocardial Infarction—Results of the CHIARA MIA 1 Trial.

Published in:

Clinical Pharmacology in Drug Development, 2019, v. 8, n. 7, p. 942, doi. 10.1002/cpdd.633

By:

Düngen, Hans‐Dirk;
Kober, Lars;
Nodari, Savina;
Schou, Morten;
Otto, Christiane;
Becka, Michael;
Kanefendt, Friederike;
Winkelmann, Bernhard R.;
Gislason, Gunnar;
Richard, Frank;
Nielsen, Olav Wendelboe;
Gheorghiade, Mihai;
Senni, Michele

Publication type:

Article